Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, reposted from World Federation of Hemophilia on LinkedIn:
”I’m proud to share this important milestone: Takeda has renewed its 5-year agreement with the WFH and WFH_USA—furthering our support for the WFH Humanitarian Aid Program!
Together with other partners, we are working to expand access, drive equity, and change lives for people living with inherited bleeding disorders globally.”
Quoting World Federation of Hemophilia‘s post:
”The WFH and WFH USA are pleased to announce that Takeda has signed a 5-year agreement renewal with the WFH Humanitarian Aid Program from 2026 to 2030!
The agreement is for the donation of treatment product, as well as a financial commitment to cover it’s handling, storage and shipping. Learn more.”
Stay updated with Hemostasis Today.
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency
-
Mar 14, 2026, 19:28Vishnu Priya Pulipati: Statins Beyond Cholesterol for Plaque Biology and Cardiovascular Risk Reduction